Agios Pharmaceuticals Inc

Financials

Cash from operating activities 290.76 M407.32 M309.48 M296.06 M389.84 M372.98 M 372.98 M Cash from investing activities 75.75 M1.25 B243.26 M239.57 M363.44 M377.18 M 377.18 M Cash from financing activities 261.52 M765.77 M2.35 M5.43 M14.44 M8.68 M 8.68 M Free cash flow 275.85 M401.58 M304.6 M295.06 M388.16 M368.66 M 368.66 M

Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.

AGIO

Financials

Agios Pharmaceuticals Inc

ニュース

Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss

トゥルーイスト証券、アジオス製薬の目標株価を39ドルに引き上げ―パイプライン進展を評価

Truist Securities raises Agios Pharma stock price target to $39 on pipeline progress

【決算速報】アギオス・ファーマシューティカルズ、売上高は予想を上回り、利益は予想を上回る結果に

Agios Pharm earnings beat by $0.09, revenue topped estimates

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates

Agios Pharm set to report earnings amid thalassemia drug rollout

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Williams to Report Q4 Earnings: What Surprise Awaits Investors?

Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:AGIO) 2026-01-14

Agios begins U.S. launch of thalassemia drug following FDA approval